The AD-SMART study will test repurposed drugs — metformin and atomoxetine — simultaneously in people with Alzheimer’s disease across more than 30 sites.
AD-SMART — the Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial — is described by its organisers as the first of its kind in Alzheimer’s. The trial’s design could cut years from the search for effective treatments.
UK trial tests existing diabetes and ADHD drugs for Alzheimer's
- Two medicines already used in the NHS — metformin for Type 2 diabetes and atomoxetine for ADHD — will be tested as possible Alzheimer’s treatments.
- Rather than one drug per trial, several treatments are tested at once; ones that show no promise are stopped quickly, and then testing something else can start.
- The trial aims to recruit 1,200 patients aged 55 or over with a confirmed diagnosis of Alzheimer’s, or mixed Alzheimer’s and vascular dementia, and the AD-SMART team expect to finish evaluating the first drugs in 2030.
Why metformin and atomoxetine were chosen
Repurposing is a deliberate strategy. Because metformin and atomoxetine are already used in the NHS, their side-effect profiles are documented.
How a “SMART” platform trial works
In a standard trial, one drug is tested. A multi-arm adaptive randomised trial instead runs several treatments at the same time.
Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.”
The model has a precedent. Siddharthan Chandran, professor of neurology and director of UK DRI, pointed to MND-SMART, a similar platform trial for motor neuron disease. “We already know this model works,” he said.
Who is being recruited, and where
| Trial element | Detail |
|---|---|
| Drugs tested first | Metformin (Type 2 diabetes), atomoxetine (ADHD) |
| Target recruitment | 1,200 patients, aged 55 or over |
| Eligible diagnoses | Alzheimer’s, or mixed Alzheimer’s and vascular dementia |
| Sites | More than 30 planned overall; up to 20 NHS sites expected to open over the next 12-18 months |
| Evaluation of first drugs | Expected to finish in 2030 |
A participant’s view
Heather Ransome, 67, was diagnosed with Alzheimer’s in 2024 and is one of the first trial participants. Before her diagnosis, she and her partner enjoyed cruises and coach holidays in retirement, and she worries about her condition getting worse.
“Getting involved with AD-SMART has given me some hope for the future.”
She described the practical burden as modest: “It’s not too taxing, just some extra tablets to take every day.“
What the evidence does and doesn’t say yet
Alzheimer’s is the most common type of dementia, affecting around 600,000 people in the UK.
Interested participants should contact the AD-SMART team
People interested in joining AD-SMART should speak to the team and anyone who thinks they might be eligible should sign up and speak to the team.
The next step
References
- Healthcare Today — Pioneering UK trial to use repurposed drugs to treat Alzheimer’s
- Medscape — New UK Trial Tests Repurposed Drugs for Alzheimer’s
Readers should consult a qualified healthcare professional about diagnosis, treatment, or trial participation.
Keep reading
- Cardiologists Warn Holiday Dishes Pack Sodium, Fat, Sugar; Offer Swaps
- Psychologist Warns Sick Leave Caps Ignore Root Mental Health Crisis
- Nvidia Slows CEO Search, Plans Higher Pay to Retain Staff After Huang Exit (world-today-journal.com)
- New UK AD-SMART Trial to Accelerate Alzheimer’s Treatment Testing via Repurposed Drugs (archynewsy.com)